BB Biotech Overview
- Founded
-
1993
- Status
-
Public
- Stock Symbol
-
BBZA
- Investments
-
77
- Share Price
-
$57.34
- (As of Monday Closing)
BB Biotech General Information
Description
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.
Contact Information
Primary Industry
Other Capital Markets/Institutions
Stock Exchange
FRA
Primary Office
- Schwertstrasse 6
- 8200 Schaffhausen
- Switzerland
+41 052 000 00 00
BB Biotech Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $57.34 | $57.42 | $51.10 - $73.64 | $3.13B | 54.8M | 2.8K | -$6.81 |
BB Biotech Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 3,627,667 | 3,627,667 | 4,740,065 | 4,824,966 |
| Revenue | (327,811) | (327,811) | (376,874) | 787,986 |
| Net Income | (374,739) | (374,739) | (442,781) | 736,067 |
| Total Assets | 3,293,342 | 3,293,342 | 3,986,524 | 4,536,140 |
| Total Debt | 391,527 | 391,527 | 388,360 | 72,109 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
BB Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BB Biotech Executive Team (19)
BB Biotech Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 00000000 00. | The Medicines Company | Vice Chairman | 000 0000 |
| 00000 00000000 00. | Self | Chairman of the Board | 000 0000 |
| 0000 0000000 00.0 | Self | Board Member | 000 0000 |
| 000000 000 000000 | BB Biotech | Board Member | 000 0000 |
BB Biotech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BB Biotech Investments & Acquisitions (77)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 0000000 | 22-Sep-2022 | 00000 0000 | 00000 | Drug Discovery | |
| 00000 0000000 | 22-Apr-2021 | 0000 | Drug Discovery | ||
| 00000 0000 00 | 12-Feb-2021 | 0000 | Drug Discovery | ||
| 00000000000 | 12-Feb-2021 | 0000 | Drug Discovery | ||
| Argenx | 05-Feb-2021 | PIPE | 00.000 | Biotechnology |
BB Biotech ESG
Risk Overview
Risk Rating
Updated October, 27, 2022
23.72 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,231
Rank
00.00
Percentile
Diversified Financials
Industry
00 of 867
Rank
00.00
Percentile
Asset Management and Custody Services
Subindustry
00 of 389
Rank
00.00
Percentile
BB Biotech Exits (43)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000 0000000000 | 01-Jan-2020 | 0000 | Completed |
|
|
| 0000 000000 | 01-Jan-2019 | 0000 | 000 | Completed |
|
| 000000 00000000000 | 08-Aug-2018 | 0000 | 00.000 | Completed |
|
| 0000000 0000000000 | 01-Feb-2018 | 00000 00000 00 | 00000 | Completed |
|
| Radius Health | 05-Jun-2017 | PIPE | Completed |
|